JOHN KEMP: Open Payments
NPI 1053967463 · NORWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,895 in 114 payments from 13 companies in 2025. Trend: 2023 $1,759 · 2024 $2,076 · 2025 $2,895
Food & beverage: $2,883Education: $12
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 43 | $619 |
| Neurocrine BioSciences, Inc. | 23 | $530 |
| Vanda Pharmaceuticals Inc. | 11 | $324 |
| ABBVIE INC. | 6 | $295 |
| Janssen Pharmaceuticals, Inc | 3 | $272 |
| Axsome Therapeutics, Inc. | 2 | $220 |
| E.R. Squibb & Sons, L.L.C. | 8 | $154 |
| Teva Pharmaceuticals USA, Inc. | 3 | $143 |
| Alkermes, Inc. | 9 | $138 |
| Otsuka America Pharmaceutical, Inc. | 2 | $93 |
Products named: CAPLYTA, INGREZZA, FANAPT, VRAYLAR, INVEGA SUSTENNA, Auvelity, COBENFY, UZEDY.
Industry payments across CT — which companies pay providers there.
